BioSpace News Archive

American Regent announces the launch and availability of Potassium Phosphates Injection, USP, which is FDA-approved and therapeutically equivalent to Potassium Phosphates.1 Potassium Phosphates Injection, USP is indicated as a source of phosphorus:

Allyx Therapeutics today disclosed its plans to present the Phase 1 single ascending dose study results at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) meeting in Boston on October 27, 2023.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the third quarter of 2023 on Thursday, November 2, 2023, following the close of market.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its third quarter 2023 financial results after the close of the U.S. financial markets on Thursday, November 9, 2023.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, November 2, 2023, following the release of its third quarter 2023 financial results.

Equillium, Inc. today announced that abstracts were accepted for poster presentations at the annual meetings of the American Society of Nephrology (ASN) and the American College of Rheumatology (ACR).

Hummingbird Bioscience and Endeavor BioMedicines (“Endeavor”), a clinical-stage company targeting the drivers of fibrosis and oncology, today announced that Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s antibody-drug conjugate (ADC), HMBD-501.

Persephone Biosciences Inc. today announced the launch of its Food as Medicine clinical study, AMBROSIA (NCT06091813).

60 Degrees Pharmaceuticals, Inc. will present a poster titled, “Long-term safety of the tafenoquine antimalarial chemoprophylaxis regimen, a 12-month, randomized double-blind placebo-controlled trial” at the International Lyme & Associated Diseases Society annual conference in Boston on October 21, 2023.

Flare Therapeutics Inc. today announced that the first patients have been dosed in the company’s phase 1 study to assess the safety and tolerability of FX-909, a first-in-class small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), a master regulator of the luminal lineage.